A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets

A Two Part, Open Label, Randomized, Phase I Bioequivalence Study Comparing the Fixed Dose Combination Dapagliflozin/Metformin IR Tablet (2.5 mg/850 mg or 5 mg/1000 mg) vs. the Free Combination of Dapagliflozin and Metformin IR Tablets, in Healthy Volunteers, in the Fed State

The primary objective of the study is to establish if the same amount of drug is absorbed into the blood after ingesting a combination dapagliflozin/metformin tablet vs. the individual dapagliflozin tablet and individual metformin tablet.

Inclusion Criteria:

• Female healthy volunteers must be post-menopausal (cessation of menses >1year), be surgically sterile (documented) or hysterectomy or on abstinence
• Have normal physical exam, vital signs Electrocardiogram (ECG) findings, and laboratory values

Exclusion Criteria:

• Use of prescription medication for a chronic or acute medical condition within 3 weeks of randomization
• History of allergy to metformin
• Previous participation in an AstraZeneca (AZ) or BristolMyers-Sqibb dapagliflozin study